Development and Manufacture of Pharmaceutical Dosage Forms for Treatment of Substance Abuse Disorders

SOL #: 75N98026R00007Sources Sought

Overview

Buyer

Health And Human Services
National Institutes Of Health
NATIONAL INSTITUTES OF HEALTH NIDA
Bethesda, MD, 20892, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in the Physical (541715)

PSC

Health R&D Services; Health Care Services; Basic Research (AN11)

Set Aside

No set aside specified

Timeline

1
Posted
Feb 17, 2026
2
Response Deadline
Mar 4, 2026, 2:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institute on Drug Abuse (NIDA), under the National Institutes of Health, is conducting market research through a Sources Sought Notice to identify qualified small businesses capable of developing and manufacturing pharmaceutical dosage forms for the treatment of substance abuse disorders. This effort aims to inform NIDA's acquisition strategy, including potential set-asides, for a future Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Capability statements are due March 4, 2026, at 9:00 AM ET.

Scope of Work

NIDA is seeking capabilities for comprehensive pharmaceutical development and manufacturing, including:

  • Pre-formulation and formulation studies of drug substances.
  • Manufacturing and packaging of finished dosage forms and placebos.
  • Analytical method development, validation, and establishment of specifications.
  • Conducting stability studies.
  • Maintaining storage facilities for drug substances and finished products, including controlled substances.
  • Shipping drug substances and dosage forms to designated NIDA sites.
  • Generating reports and data for Investigational New Drug (IND), New Drug Application (NDA), and Drug Master File (DMF) preparations.
  • Ensuring compliance with FDA's current Good Manufacturing Practice (cGMP) and Good Laboratory Practices (GLP), and obtaining appropriate DEA Registrations.

Contract & Timeline

  • Type: Sources Sought / Market Research (for an anticipated IDIQ Task Order contract)
  • Anticipated Duration: Five (5) years
  • Set-Aside: Market research for potential small business set-asides; NIDA is specifically interested in small business sources.
  • Response Due: March 4, 2026, 9:00 AM ET
  • Published: February 17, 2026

Submission & Evaluation

Interested companies must submit a capability statement addressing their ability to meet the project requirements. Statements should be in Microsoft Word or Adobe PDF, 11-11pt font, 8.5x11 paper, 1" margins, and limited to ten (10) pages (excluding cover page, executive summary, and references). Submissions must include total employees, personnel qualifications, GSA Schedule/GWACs (if applicable), company name, Unique Entity ID, physical address, and points of contact. Responses will be used for market research to determine small business availability and inform the acquisition strategy.

Additional Notes

This notice is for information and market research purposes only and is not a solicitation for proposals. No award will be made as a result of this notice, and the Government will not reimburse costs incurred by respondents. Organizations not considered small businesses under the applicable NAICS code should not respond.

People

Points of Contact

Scott DuernbergerPRIMARY
Joshua T LazarusSECONDARY

Files

Files

Download

Versions

Version 1Viewing
Sources Sought
Posted: Feb 17, 2026
Development and Manufacture of Pharmaceutical Dosage Forms for Treatment of Substance Abuse Disorders | GovScope